Industry and FDA appear aligned on a number of topics in the generic drug user fee renewal negotiations as the clock ticks to complete the negotiations and send the agreement to Congress.
Both sides have reached "tentative, conceptual alignment" on ANDA review goals and program enhancements, drug master file program enhancements and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?